Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Circulating T-regulatory cells in neuroblastoma: a pilot prospective study.

Literature DB >> 24684178

Circulating T-regulatory cells in neuroblastoma: a pilot prospective study.

Tvsvgk Tilak¹, Surender Sherawat, Sandeep Agarwala, Ritu Gupta, Sreenivas Vishnubhatla, Sameer Bakhshi.

Abstract

The objective of our study was to determine baseline Tregs in neuroblastoma patients and correlate with patient characteristics, their change with therapy and at relapse/progression. Flow-cytometric analysis for Treg cells [CD4+CD25+FoxP3+] was done in 14 de novo neuroblastoma patients at diagnosis, post-neoadjuvant chemotherapy and at relapse/progression, along with six healthy controls. Patients had significantly higher baseline Treg frequency than controls [Mean 9.84 ± 3.84 vs 3.16 ± 1.49, P < .001]; higher mean Treg frequency in patients with tumors >10 cm (P = .004) and there was significant reduction in Treg frequency with neoadjuvant chemotherapy when compared with the baseline value [Mean 3.07 ± 1.24 vs 9.72 ± 3.84, P = .007].

Entities: Disease Gene Species

Keywords: T-regulatory; chemotherapy; neuroblastoma

Mesh：

Substances：
Antineoplastic Agents

Year: 2014 PMID： 24684178 DOI： 10.3109/08880018.2014.886002

Source DB: PubMed Journal: Pediatr Hematol Oncol ISSN： 0888-0018 Impact factor: 1.969

Keyword Cloud
Cited

9 in total

1. CD4⁺CD25^hiCD127^- Treg and CD4⁺CD45R0⁺CD49b⁺LAG3⁺ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.

Authors: Fabio Morandi; Sarah Pozzi; Sebastiano Barco; Giuliana Cangemi; Loredana Amoroso; Barbara Carlini; Vito Pistoia; Maria Valeria Corrias
Journal: Oncoimmunology Date: 2016-10-24 Impact factor: 8.110

Review 2. Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.

Authors: Hamid Bassiri; Adriana Benavides; Michelle Haber; Susan K Gilmour; Murray D Norris; Michael D Hogarty
Journal: Transl Pediatr Date: 2015-07

3. Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients.

Authors: Izhar S Batth; Long Dao; Arun Satelli; Abhisek Mitra; Sofia Yi; Hyangsoon Noh; Heming Li; Zachary Brownlee; Shouhao Zhou; Jeffrey Bond; Jing Wang; Jonathan Gill; Giselle S Sholler; Shulin Li
Journal: Int J Cancer Date: 2020-06-23 Impact factor: 7.316

4. IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.

Authors: Fabio Morandi; Michela Croce; Giuliana Cangemi; Sebastiano Barco; Valentina Rigo; Barbara Carlini; Loredana Amoroso; Vito Pistoia; Silvano Ferrini; Maria Valeria Corrias
Journal: J Immunol Res Date: 2015-04-19 Impact factor: 4.818

5. Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival.

Authors: Sara Stigliani; Michela Croce; Fabio Morandi; Paola Scaruffi; Valentina Rigo; Barbara Carlini; Carla Manzitti; Anna Rita Gigliotti; Gian Paolo Tonini; Vito Pistoia; Silvano Ferrini; Maria Valeria Corrias
Journal: Biomed Res Int Date: 2015-06-16 Impact factor: 3.411

Circulating T-regulatory cells in neuroblastoma: a pilot prospective study.

1. CD4⁺CD25^hiCD127^- Treg and CD4⁺CD45R0⁺CD49b⁺LAG3⁺ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.

Review 2. Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.

3. Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients.

4. IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.

5. Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival.

Review 6. Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

Review 7. Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions.

8. Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.

Review 9. "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.

Circulating T-regulatory cells in neuroblastoma: a pilot prospective study.

1. CD4+CD25hiCD127- Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.

Review 2. Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.

3. Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients.

4. IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.

5. Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival.

Review 6. Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

Review 7. Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions.

8. Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.

Review 9. "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.

1. CD4⁺CD25^hiCD127^- Treg and CD4⁺CD45R0⁺CD49b⁺LAG3⁺ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.